

# Antti Tanskanen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4213008/publications.pdf>

Version: 2024-02-01

69  
papers

3,664  
citations

279798

23  
h-index

133252

59  
g-index

69  
all docs

69  
docs citations

69  
times ranked

3820  
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study. <i>Psychological Medicine</i> , 2023, 53, 833-843.	4.5	1
2	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 166-175.	4.3	26
3	Automated multi-dose dispensing in persons with and without Alzheimer's disease's impacts on pharmacotherapy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 513-521.	1.9	0
4	Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study. <i>Journal of Affective Disorders</i> , 2022, 299, 528-535.	4.1	4
5	Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 655-663.	4.3	19
6	Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort. <i>Addiction</i> , 2022, 117, 1683-1691.	3.3	5
7	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. <i>JAMA Psychiatry</i> , 2022, 79, 210.	11.0	47
8	Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. <i>Lancet Psychiatry</i> , 2022, 9, 353-362.	7.4	15
9	Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study. <i>Journal of Affective Disorders</i> , 2022, 308, 236-242.	4.1	8
10	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	6.1	67
11	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 774-784.	4.3	9
12	Prevalence of oral anticoagulant use among people with and without Alzheimer's disease. <i>BMC Geriatrics</i> , 2022, 22, .	2.7	2
13	Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 23-30.	4.3	35
14	Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 1.	3.6	40
15	Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nationwide cohort of 125,556 patients. <i>Addiction</i> , 2021, 116, 1990-1998.	3.3	16
16	Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder. <i>Schizophrenia Bulletin</i> , 2021, 47, 1099-1107.	4.3	10
17	Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients. <i>Schizophrenia Research</i> , 2021, 228, 367-372.	2.0	10
18	Morbidity and mortality in schizophrenia with comorbid substance use disorders. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 42-49.	4.5	25

#	ARTICLE	IF	CITATIONS
19	Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 487-494.	4.5	5
20	Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer's Disease. <i>Clinical Epidemiology</i> , 2021, Volume 13, 295-307.	3.0	2
21	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. <i>Schizophrenia Bulletin</i> , 2021, 47, 1621-1630.	4.3	24
22	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1611-1620.	4.3	33
23	Does Recent Hospitalization Increase Antipsychotic Initiation Among Community Dwellers With Alzheimer's Disease?. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1543-1547.e3.	2.5	5
24	Switches and early discontinuations of antidepressant medication in young adults with depression. <i>Journal of Affective Disorders</i> , 2021, 295, 1474-1481.	4.1	3
25	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. <i>Lancet Psychiatry</i> , 2021, 8, 883-891.	7.4	50
26	Persistence of antidepressant use among refugee youth with common mental disorder. <i>Journal of Affective Disorders</i> , 2021, 294, 831-837.	4.1	4
27	Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences. <i>Nordic Journal of Psychiatry</i> , 2021, 75, 315-322.	1.3	15
28	Changes in the use of diabetes drugs among community-dwelling people with Alzheimer's disease. <i>BMC Geriatrics</i> , 2021, 21, 701.	2.7	2
29	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. <i>Psychological Medicine</i> , 2020, 50, 1356-1367.	4.5	26
30	20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i> , 2020, 19, 61-68.	10.4	232
31	Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease. <i>International Journal of Cardiology</i> , 2020, 300, 221-225.	1.7	4
32	Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e963-e972.	3.6	60
33	Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study. <i>Journal of Affective Disorders</i> , 2020, 277, 885-892.	4.1	20
34	Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia. <i>Medical Care</i> , 2020, 58, 763-769.	2.4	8
35	Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland. <i>JAMA Network Open</i> , 2020, 3, e2019029.	5.9	24
36	Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease. <i>Neurology</i> , 2020, 94, e2099-e2108.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 711-718.	1.9	13
38	Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1488-1494.e3.	2.5	5
39	Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 807-816.	2.6	7
40	Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study. <i>Pain</i> , 2019, 160, 417-423.	4.2	20
41	Concomitant use of benzodiazepines and opioids in community-dwelling older people with or without Alzheimer's disease—A nationwide register-based study in Finland. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 280-288.	2.7	6
42	Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 417-425.	1.9	8
43	Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 751-758.	2.5	4
44	Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. <i>JAMA Psychiatry</i> , 2018, 75, 347.	11.0	116
45	20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2018, 175, 765-773.	7.2	134
46	Research Priorities for Optimizing Geriatric Pharmacotherapy: An International Consensus. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 193-199.	2.5	35
47	Comparison of dispensed medications and forensic toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1112-1122.	1.9	24
48	Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 387-395.	2.6	11
49	Systemic Estrogen Use and Discontinuation After Alzheimer's Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study. <i>Drugs and Aging</i> , 2018, 35, 985-992.	2.7	3
50	Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 686.	11.0	460
51	Screening approach for identifying candidate drugs and drug-drug interactions related to hip fracture risk in persons with Alzheimer disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 875-889.	1.9	3
52	Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 107-118.	2.6	24
53	No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1802-1808.	0.4	69
54	Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 59.	6.2	7

#	ARTICLE	IF	CITATIONS
55	Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. <i>Lancet Psychiatry</i> , 2017, 4, 547-553.	7.4	39
56	Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer's disease in 2005-2011. <i>PLoS ONE</i> , 2017, 12, e0173450.	2.5	5
57	Drug exposure in register-based research – An expert-opinion based evaluation of methods. <i>PLoS ONE</i> , 2017, 12, e0184070.	2.5	31
58	Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e257-e263.	2.2	23
59	Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. <i>Clinical Epidemiology</i> , 2016, Volume 8, 363-371.	3.0	61
60	Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study. <i>BMJ Open</i> , 2016, 6, e012100.	1.9	75
61	Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease – exposure-matched cohort study. <i>BMC Geriatrics</i> , 2016, 16, 204.	2.7	43
62	Drug use in persons with and without Alzheimer's disease aged 90 years or more. <i>Age and Ageing</i> , 2016, 45, 900-904.	1.6	14
63	Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study. <i>American Journal of Psychiatry</i> , 2016, 173, 600-606.	7.2	160
64	Month and Season of Birth as a Risk Factor for Alzheimer's Disease: A Nationwide Nested Case-control Study. <i>Journal of Preventive Medicine and Public Health</i> , 2016, 49, 134-138.	1.9	9
65	From prescription drug purchases to drug use periods – a second generation method (PRE2DUP). <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 21.	3.0	137
66	From prescriptions to drug use periods - things to notice. <i>BMC Research Notes</i> , 2014, 7, 796.	1.4	12
67	Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 435-440.	1.4	18
68	Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research – the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study. <i>Clinical Epidemiology</i> , 2013, 5, 277.	3.0	43
69	11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11) <a href="#">Tj ETQq1 1 0.784314 rgBT/Ov</a>	13.7	15179